Demographic and Clinical Features of 1,641 Patients with Alopecia Areata, Alopecia Totalis, and Alopecia Universalis: A Single-Center Retrospective Study

被引:16
作者
Uzuncakmak, Tugba Kevser [1 ]
Engin, Burhan [1 ]
Serdaroglu, Server [1 ]
Tuzun, Yalcin [1 ]
机构
[1] Istanbul Univ Cerrahpasa, Med Fac, Dept Dermatol, Dr Erkin St, TR-34722 Istanbul, Turkey
来源
SKIN APPENDAGE DISORDERS | 2021年 / 7卷 / 01期
关键词
Alopecia areata; Alopecia totalis; Alopecia universalis; Epidemiology; AUTOIMMUNE-DISEASE; PROFILE; EPIDEMIOLOGY; PREVALENCE;
D O I
10.1159/000510880
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background/Aim: Alopecia areata (AA) is a common autoimmune hair disorder which is characterized by noncicatricial hair loss. AA commonly presents with localized patches on the scalp and face but may affect any hair-bearing region of the body leading to even more generalized involvement. AA may affect any age group, gender, and race. The current study investigates the demographic characteristics of the patients with AA and subgroups of AA including alopecia totalis (AT) and alopecia universalis (AU) and the prevalence of disease, sex, and age distribution and seasonal variation retrospectively in a tertiary dermatology clinic in Turkey. Materials and Methods: In this retrospective, cross-sectional study, 1,641 patients diagnosed with AA, AT, and AU in the dermatology clinic of a public university hospital were included. The dermatology outpatient database was reviewed retrospectively. The diagnosis of AA was based on patient history, clinical examinations, and histopathologic findings. Results: Fifty-four thousand one hundred sixty-eight patients were admitted to our outpatient clinic in 4 years time, and 1,641 were diagnosed as having AA, AT, and AU. One thousand three hundred ninety-two patients (84.8%) had AA, 81 (4.9%) had AT, and 168 (10.2%) had AU. Among the 1,641 patients included in the study, 877 were females (53.4%) and 764 were males (46.6%). The mean age was 29.86 +/- 14.48 years in AA, 29.50 +/- 16.18 in AT, and 32.81 +/- 14.48 in AU; 77.4, 72.8, and 68.5% of patients were aged under 40 years in AA, AT, and AU. There was no statistically significant difference in seasonal presentation times. Conclusion: AA is affecting approximately 2% of the general population without any sex, race, or age group predilection. In this study, we found a lower prevalence of AA in the pediatric age group in comparison with adults. This finding may support the hypothesis of the increasing prevalence of AA over time. The higher ratio of AA regarding this study may support that the frequency of AA and subtypes varies between regions.
引用
收藏
页码:8 / 12
页数:5
相关论文
共 50 条
  • [41] Patient characteristics and patterns of treatment for moderate to severe alopecia areata: a single-institution retrospective study
    Xiong, Grace
    Zhou, Ted
    Abu-Hilal, Mohannad
    [J]. ARCHIVES OF DERMATOLOGICAL RESEARCH, 2025, 317 (01)
  • [42] A randomized placebo-controlled single-center pilot study of the safety and efficacy of apremilast in subjects with moderate-to-severe alopecia areata
    Daniela Mikhaylov
    Ana Pavel
    Christopher Yao
    Grace Kimmel
    John Nia
    Peter Hashim
    Anjali S. Vekaria
    Mark Taliercio
    Giselle Singer
    Rachel Karalekas
    Danielle Baum
    Yasaman Mansouri
    Mark G. Lebwohl
    Emma Guttman-Yassky
    [J]. Archives of Dermatological Research, 2019, 311 : 29 - 36
  • [43] A randomized placebo-controlled single-center pilot study of the safety and efficacy of apremilast in subjects with moderate-to-severe alopecia areata
    Mikhaylov, Daniela
    Pavel, Ana
    Yao, Christopher
    Kimmel, Grace
    Nia, John
    Hashim, Peter
    Vekaria, Anjali S.
    Taliercio, Mark
    Singer, Giselle
    Karalekas, Rachel
    Baum, Danielle
    Mansouri, Yasaman
    Lebwohl, Mark G.
    Guttman-Yassky, Emma
    [J]. ARCHIVES OF DERMATOLOGICAL RESEARCH, 2019, 311 (01) : 29 - 36
  • [44] Oral Tofacitinib for the Management of Moderate to Severe Alopecia Areata in Children and Adolescents: A Retrospective Study of 36 Patients
    Mahajan, Rahul
    Mehta, Hitaishi
    De, Dipankar
    Handa, Sanjeev
    [J]. PEDIATRIC DERMATOLOGY, 2025,
  • [45] Real-world effectiveness and safety of tofacitinib for alopecia areata: A retrospective cohort study of 202 patients
    Cranwell, William
    Meah, Nekma
    Wall, Dmitri
    Bevin, Bhoyrul
    Laita, Bokhari
    Sinclair, Rodney D.
    [J]. AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2024, 65 (06) : 505 - 513
  • [46] Efficacy, safety, and Pharmacoeconomics of Three Common Strategies for Pediatric Alopecia Areata Patients: A Retrospective Cohort Study
    Zhou, Jiong
    Yang, Yang
    Xu, Mengjun
    Lyu, Zhongfa
    Wu, Xianjie
    [J]. CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY, 2023, 16 : 2947 - 2956
  • [47] Predictive factors for treatment responses to baricitinib in severe alopecia areata: A retrospective, multivariate analysis of 70 cases from a single center
    Wada-Irimada, Moyuka
    Takahashi, Takehiro
    Sekine, Mana
    Okazaki, Toshiki
    Takahashi, Takuya
    Chiba, Tomoko
    Yamazaki, Emi
    Shido, Kosuke
    Takahashi, Toshiya
    Mizuashi, Masato
    Asano, Yoshihide
    [J]. JOURNAL OF DERMATOLOGY, 2025, : 701 - 711
  • [48] Prevalence of Thyrotropin Receptor Antibodies and Clinical Profile of Patients with Alopecia Areata: A Cross-Sectional Study
    Stefanis, Athanasios J.
    Fialova, Alena
    Arenberger, Petr
    [J]. SKIN APPENDAGE DISORDERS, 2025, 11 (01) : 1 - 8
  • [49] Effectiveness of dupilumab in the treatment of alopecia areata in patients with concurrent atopic dermatitis: a real-life retrospective study
    Tavoletti, Gianluca
    Valtellini, Luca
    Mattioli, Maria A.
    Chiei-Gallo, Alessandra
    Barbareschi, Mauro
    Marzano, Angelo V.
    Ferrucci, Silvia M.
    [J]. INTERNATIONAL JOURNAL OF DERMATOLOGY, 2024, 63 (12) : e434 - e436
  • [50] Effectiveness of Generic Tofacitinib in the Treatment of Patients with Mild Alopecia Areata in China: A Retrospective Real-World Study
    Jian, Jia
    Li, Min
    Huang, Jundong
    Shi, Wei
    [J]. JOURNAL OF CUTANEOUS MEDICINE AND SURGERY, 2025, 29 (01) : 78 - 79